Program
botulinum toxin type A
Also written as “Botulinum toxin type A”, “Botulinum Toxin Type A” and “botulinum toxin Type A”.
In AbbVie’s pipeline, SNAP-25
. Its studies are mostly in Torticollis · Urinary Bladder, Overactive · Migraine Disorders · Muscle Spasticity · Stroke, led by 27 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 814 open or running | phase 4since Sep 13, 2005 | Jan 29, 2004 | Jun 2027phase 4 · NCT07794891 |
| Ipsen | 442 open or running | phase 4since Sep 13, 2005 | Aug 23, 2005 | none ahead |
| Merz Pharma | 425 open or running | phase 4since Oct 8, 2007 | Nov 30, 2006 | Mar 2027phase 3 · NCT07018700 |
| Medy-Tox | 240 open or running | phase 4since Nov 25, 2010 | Nov 4, 2010 | none ahead |
| Revance | 190 open or running | phase 3since Jan 18, 2013 | Aug 27, 2009 | none ahead |
| Galderma Group | 150 open or running | phase 4since Mar 5, 2014 | Nov 16, 2009 | none ahead |
| GlaxoSmithKline | 100 open or running | phase 3since Dec 6, 2006 | Dec 6, 2006 | none ahead |
| Hugel | 101 open or running | phase 4since Aug 19, 2018 | Feb 5, 2013 | none ahead |
| anterios-inc | 50 open or running | phase 2since Feb 9, 2011 | Feb 9, 2011 | none ahead |
| Daewoong Pharmaceutical | 50 open or running | phase 3since Sep 16, 2013 | Sep 16, 2013 | none ahead |
| Eirion Therapeutics | 50 open or running | phase 2since Oct 27, 2017 | Oct 27, 2017 | none ahead |
| Croma-Pharma | 30 open or running | phase 3since Oct 22, 2015 | Oct 22, 2015 | none ahead |
| Johnson & Johnson | 30 open or running | phase 3since Sep 10, 2008 | Sep 10, 2008 | none ahead |
| Sinopharm | 30 open or running | phase 3since Oct 29, 2014 | Oct 29, 2014 | none ahead |
| edigene-guangzhou-inc | 20 open or running | phase 1since Jun 4, 2021 | Jun 4, 2021 | none ahead |
| evolus-inc | 20 open or running | phase 3since Jan 6, 2015 | Jan 6, 2015 | none ahead |
| li-nguyen | 20 open or running | phase 2since Feb 26, 2014 | Feb 26, 2014 | none ahead |
| asis-corporation | 10 open or running | phase 2since Feb 26, 2014 | Feb 26, 2014 | none ahead |
| atgc-co-ltd | 10 open or running | phase 2since Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Azidus Brasil | 10 open or running | phase 3since Aug 10, 2010 | Aug 10, 2010 | none ahead |
| biolab-sanus-farmaceutica | 10 open or running | phase 3since Sep 29, 2009 | Sep 29, 2009 | none ahead |
| espad-pharmed | 10 open or running | phase 3since Apr 19, 2025 | Apr 19, 2025 | none ahead |
| Huons Global | 11 open or running | phase 3since Jul 18, 2023 | Jul 18, 2023 | none ahead |
| inibio-co-ltd | 10 open or running | phase 3since May 26, 2026 | May 26, 2026 | none ahead |
| LEO Pharma | 10 open or running | phase 1since Oct 9, 2015 | Oct 9, 2015 | none ahead |
| pacific-pharmaceuticals | 10 open or running | phase 3since May 20, 2008 | May 20, 2008 | none ahead |
| rmw-testing | 10 open or running | phase 2since Aug 4, 2023 | Aug 4, 2023 | none ahead |
- Named in AbbVie’s own pipeline as
GemibotulinumtoxinA
, phase 2, as of Jul 30, 2026 (source).
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Laboratório Químico Farmacêutico Bergamo Ltda., Synteract and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Mar 29, 2019.
- Aug 4, 2023rmw-testing’s first study: phase 2 study in Pulmonary Disease, Chronic ObstructiveNew to rmw-testingrmw-testing · NCT06003049 · 40 enrolled · United States
- Sep 14, 20232 phase 3 studiesIpsen · NCT06047457, NCT06047444
- Oct 13, 2023Phase 2 study in Neuralgia, PostherpeticMerz Pharma · NCT06091020 · 123 enrolled · Bulgaria, France, Germany and more
- Jan 15, 2025Phase 4 study in Facial ContouringAbbVie · NCT06783621 · 130 enrolled · United States
- Jan 21, 2025Phase 3 study in Forehead LinesAbbVie · NCT06794866 · 150 enrolled · Japan
- Apr 19, 2025espad-pharmed’s first study: phase 3 study in Glabellar LinesNew to espad-pharmedespad-pharmed · NCT06946160 · 146 enrolled · Iran, Islamic Republic of
- Jun 4, 20252 phase 3 studiesMerz Pharma · NCT07018713, NCT07018700
- Aug 7, 2025Phase 3 study in Neuromuscular AgentsMerz Pharma · NCT07122193 · 300 enrolled · United States, Puerto Rico
- Sep 29, 2025Phase 3 study in Neuromuscular AgentsMerz Pharma · NCT07210463 · 300 enrolled · France, Germany, Poland and more
- Nov 7, 2025Phase 2 study in Hernia, VentralAbbVie · NCT07226791 · 200 planned · United States
- May 26, 2026inibio-co-ltd’s first study: phase 3 study in Glabellar LinesNew to inibio-co-ltdinibio-co-ltd · NCT07622004 · 292 enrolled · South Korea
- Jun 23, 2026Phase 2 study in Upper Limb Essential TremorAbbVie · NCT07673107 · 94 planned · United States, Canada
- Aug 27, 2026Phase 4 study in Jawline and Neck AppearanceAbbVie · NCT07794891 · 100 planned · Canada
- Oct 7, 2026Phase 2 study in Upper Facial LinesAbbVie · NCT07871513 · 300 planned · United States
Ahead
- Mar 2027Primary completion: phase 3 study in Chronic MigraineMerz Pharma · NCT07018713
- Mar 2027Primary completion: phase 3 study in Episodic MigraineMerz Pharma · NCT07018700
- Jun 2027Primary completion: phase 4 study in Jawline and Neck AppearanceAbbVie · NCT07794891
- Jun 2028Primary completion: phase 2 study in Upper Facial LinesAbbVie · NCT07871513
TargetBeta
“SNAP-25”the company's pipeline, read by Claude · source
“Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme”ChEMBL 37, by rule
Other programs on SNAP25
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| trenibotulinumtoxinErule | AbbVie | phase 3 | 11 |
| prabotulinumtoxin Arule | aeon-biopharma-inc | phase 3 | 9 |
Studies
The newest 60 of 285 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07871513Upper Facial Lines · United States | 2 | Recruiting | AbbVie | Jun 2028 | 300 |
| NCT07794891Jawline and Neck Appearance · Canada | 4 | Recruiting | AbbVie | Jun 2027 | 100 |
| NCT07673107Upper Limb Essential Tremor · United States, Canada | 2 | Recruiting | AbbVie | Nov 2028 | 94 |
| NCT07622004Glabellar Lines · South Korea | 3 | Completed | inibio-co-ltd | Jan 30, 2022 | 292 |
| NCT07226791Hernia, Ventral · United States | 2 | Recruiting | AbbVie | Sep 2028 | 200 |
| NCT07210463Neuromuscular Agents · France, Germany, Poland and more | 3 | Active, not recruiting | Merz Pharma | Aug 5, 2026 | 300 |
| NCT07122193Neuromuscular Agents · United States, Puerto Rico | 3 | Active, not recruiting | Merz Pharma | Jun 5, 2026 | 300 |
| NCT07018713Chronic Migraine · United States, Austria, Canada and more | 3 | Active, not recruiting | Merz Pharma | Mar 2027 | 808 |
| NCT07018700Episodic Migraine · United States, Austria, Canada and more | 3 | Active, not recruiting | Merz Pharma | Mar 2027 | 997 |
| NCT06946160Glabellar Lines · Iran, Islamic Republic of | 3 | Completed | espad-pharmed | Feb 18, 2025 | 146 |
| NCT06794866Forehead Lines · Japan | 3 | Completed | AbbVie | Apr 3, 2026 | 150 |
| NCT06783621Facial Contouring · United States | 4 | Completed | AbbVie | Mar 20, 2026 | 130 |
| NCT06091020Neuralgia, Postherpetic · Bulgaria, France, Germany and more | 2 | Completed | Merz Pharma | May 7, 2025 | 123 |
| NCT06047457Episodic Migraine · United States, Canada, Czechia and more | 3 | Active, not recruiting | Ipsen | Jun 1, 2026 | 751 |
| NCT06047444Chronic Migraine · United States, Canada, Czechia and more | 3 | Active, not recruiting | Ipsen | May 28, 2026 | 759 |
| NCT06003049Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | rmw-testing | Apr 24, 2024 | 40 |
| NCT05964257Benign Masseteric Hypertrophy · Korea, Republic of | 3 | Active, not recruiting | Huons Global | Mar 7, 2024 | 188 |
| NCT05956509Muscle Spasticity · United States | 1 | Terminated | AbbVie | Jun 2, 2024 | 1 |
| NCT05801146Glabellar Lines · Korea, Republic of | 3 | Recruiting | Hugel | Mar 2025 | 272 |
| NCT05784363Enlarged Pores · United States | 1 | Completed | Merz Pharma | Jun 17, 2024 | 31 |
| NCT05773053Platysma Prominence · United States | 2 | Completed | Merz Pharma | Oct 19, 2023 | 73 |
| NCT05752123Transfusion Dependent Beta-Thalassaemia · China | – | Terminated | edigene-guangzhou-inc | Jan 29, 2024 | 2 |
| NCT05606757Hernia, Ventral · United States | 2 | Withdrawn | AbbVie | Apr 22, 2025 | 0 |
| NCT05585398N/A, as no Specific Medical Condition Will be Treated · Germany | 1 | Completed | Merz Pharma | Feb 24, 2023 | 40 |
| NCT05463965Moderate to Severe Glabellar Lines · China | 3 | Completed | Galderma Group | Jan 29, 2023 | 605 |
| NCT05217355Glabellar Frown Lines · Korea, Republic of | 2 | Completed | Medy-Tox | Jun 22, 2022 | 50 |
| NCT05152576Forehead Lines · United States | 2 | Completed | AbbVie | Sep 6, 2022 | 124 |
| NCT05134649Platysma Prominence · United States, Canada | 3 | Completed | AbbVie | Aug 18, 2023 | 292 |
| NCT05148000Glabellar Frown Lines · United States | 3 | Completed | Galderma Group | Mar 31, 2023 | 25 |
| NCT05146999Glabellar Frown Lines · United States | 3 | Completed | Galderma Group | Oct 28, 2022 | 132 |
| NCT05100199Glabellar Lines · United States | 2 | Completed | AbbVie | Dec 2, 2022 | 328 |
| NCT05013424Glabellar Lines · United States | 2 | Completed | AbbVie | Jul 7, 2022 | 92 |
| NCT04994535Platysma Prominence · United States, Belgium, Canada and more | 3 | Completed | AbbVie | Jun 14, 2023 | 426 |
| NCT04985916Lateral Canthal Lines, LCL · United States | 2 | Completed | Eirion Therapeutics | Feb 8, 2024 | 280 |
| NCT04970407Healthy Participants · United Kingdom | 1 | Completed | Ipsen | Mar 16, 2022 | 45 |
| NCT04949399Platysma Prominence · United States, Canada | 3 | Completed | AbbVie | Dec 20, 2022 | 408 |
| NCT04944953Glabellar Lines · Korea, Republic of | 1 | Completed | Hugel | Sep 2, 2021 | 38 |
| NCT04936542Upper Limb Spasticity · United States, Canada, France and more | 4 | Completed | Ipsen | Aug 26, 2025 | 464 |
| NCT04925206beta-Thalassemia · China | 1 | Terminated | edigene-guangzhou-inc | Jan 30, 2024 | 8 |
| NCT04766723Essential Tremor of the Upper Limb · United States, Canada, Poland | 2 | Completed | Merz Pharma | Apr 26, 2023 | 78 |
| NCT04622254Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) · Germany | 3 | Completed | Merz Pharma | Jun 16, 2021 | 368 |
| NCT04594213Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) · United States | 3 | Completed | Merz Pharma | Apr 15, 2021 | 362 |
| NCT04443244Benign Masseteric Hypertrophy · Korea, Republic of | 2 | Completed | Hugel | Nov 18, 2020 | 80 |
| NCT04281095Glabellar Frown Lines · Korea, Republic of | 2 | Completed | atgc-co-ltd | Apr 30, 2020 | 60 |
| NCT04281745Glabellar Frown Lines · Korea, Republic of | 4 | UNKNOWN | Medy-Tox | Jun 17, 2020 | 200 |
| NCT04247074Glabellar Frown Lines (GL) · United States, Canada | 3 | Completed | Galderma Group | Oct 2, 2020 | 413 |
| NCT04225260Glabellar Lines · United States, Puerto Rico | 3 | Completed | Galderma Group | Apr 12, 2021 | 902 |
| NCT04259086Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) · United States, Canada | 2 | Completed | Revance | Nov 2, 2020 | 48 |
| NCT04186442Urinary Bladder, Overactive · Korea, Republic of | 1 | Completed | Hugel | Apr 26, 2021 | 38 |
| NCT04143854Lateral Canthal Lines · Australia | 2 | Completed | Medy-Tox | Aug 19, 2020 | 150 |
| NCT04143815Glabellar Frown Lines · Australia | 2 | Completed | Medy-Tox | Sep 1, 2020 | 200 |
| NCT04080882Platysmal Bands · United States | 2 | Completed | Galderma Group | Dec 30, 2019 | 80 |
| NCT04073303Masseter Muscle Prominence · Canada, China, Taiwan | 3 | Completed | AbbVie | Nov 10, 2022 | 377 |
| NCT04113941Urinary Bladder, Overactive · Korea, Republic of | 3 | UNKNOWN | Medy-Tox | Apr 15, 2020 | 216 |
| NCT04171258Torticollis · Korea, Republic of | 1 | Completed | Hugel | Apr 26, 2021 | 38 |
| NCT03992404Brain Injuries, Traumatic · United States, Belgium, Canada and more | 3 | Active, not recruiting | Merz Pharma | Jun 19, 2025 | 603 |
| NCT03985982Glabellar Frown Lines · United States | 3 | Completed | Croma-Pharma | Dec 4, 2019 | 410 |
| NCT03960957Glabellar Frown Lines · United States | 3 | Completed | Galderma Group | Sep 27, 2019 | 301 |
| NCT03912805Lateral Canthal Lines, LCL · United States | 2 | Completed | Eirion Therapeutics | May 6, 2019 | 38 |
| NCT03915067Platysma Prominence · United States, Canada | 2 | Completed | AbbVie | Apr 16, 2020 | 171 |
How it is read
Names in the registry
- “Botulinum toxin type A”, 69 entries
- “Botulinum Toxin Type A”, 28 entries
- “botulinum toxin Type A”, 21 entries
- “OnabotulinumtoxinA”, 15 entries
- “NT 201”, 13 entries
Codes read as this program: ET01, GSK1358820.
Conditions, from the studies’ own filings
- Torticollis, 18 studies
- Urinary Bladder, Overactive, 17 studies
- Migraine Disorders, 16 studies
- Muscle Spasticity, 15 studies
- Stroke, 13 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.